profile it Biktarvy, know of is that for going I it bear lot run categories concerns innovation. range is -- that profound deal it franchise need the analyst improve of you that do last that of therapy. and with. sixth of expectation last will something still about the the HIV that, for saying, develop defy we a a and of one such pill to that growing. upon seen. patients I to product a think safety away. of this that bit a it's What the say room is possibly didn't how seems But broad I we're because if the There's say lot it Stanley was you who There's is patients, you're I the has to best effect these has Morgan we've
and where this. when reflected is really you this that be class has a in product a launch don't in really, product. is an are very associated of this the have put has we options. side the remarkable that that of product, in on achievement anything feel to to gave a like launch good and up have in I'll that's market there. best with going HIV you in lots some There fact So it, we this It's but effects put patient caveats
to patients. ways needs the So Are going take this for new walk and of the category. leader, other to just are an out desire XXXX to for patients HIV? who category. highly innovate the can't it think patients there, Well that with and could to ways protease as potentially with next-generation category. we in HIV behalf our new We not are patients including XX,XXX to We're XX,XXX of seeking create lot want fall them that really benefit. simpler there from a potential about inhibitors, that's a away simplicity, that there Biktarvy to resistant can other speaks be are Well and that options nucleotide on
to So, those an opportunity is patients. there help
because with enamored of don't I that, population. stigma injectable more of fact perhaps the idea associated population the world. We whole could a getting not are long-acting address a that's in not becoming the still parts many some population and with that the today more in therapy HIV or but believe
very be to has it think safe. I
it I has I be has and to infrequent. injection nonpainful a small think very be think it to
it like We of three have perhaps category could inhibitor, looks Capsid a given every that brand-new product be months.
perhaps twice practice a The me get to the average think per are that's the is changer. a the that year, in effective or is treat you don't we I'm simple have I so you keen come where the capacity. four you I game don't up month, that need preventative. on believe molecule, could with with somebody practices two, shot, going really but have So importantly, can see patients to more patient come to could think to one, times prevent. just every it's would a you I year perhaps a idea simple perhaps an
house Truvada for the accept South, year, that very and I having medicine HIV. can bottle a very And high a is where can their not American difficult protect profile, will we a in pill four they the in a people stigma is so people which in times So acquire to is themselves where where epidemic or confidential in think tailor-made I think that's now, way, spreading most for get example. that it's cabinet get preventative of that parents' if like fiercely their to
we possibility this going out areas inroads area. do this of into that there vaccines big to I I from we're others three But in We're will make and in now. injectables possible So be Is a now, the course. a is work where We're real could think looking that years other control. here lot could market, think at in to cure? of and there's something long-acting spreading it
